US Stocks Close Higher, Nasdaq Hits All-Time High
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 hours ago
0mins
Source: NASDAQ.COM
- Market Recovery: The S&P 500 rose by 0.58% and the Nasdaq 100 climbed 0.84%, reaching all-time highs, reflecting market optimism following the US-Iran ceasefire agreement, which may promote economic stability.
- Economic Data Impact: The US April core PCE price index increased by 3.3% year-on-year, meeting expectations, but the unexpected 1.1% decline in April capital goods orders indicates economic recovery fragility, potentially influencing the Fed's monetary policy decisions.
- Rising Unemployment Claims: Initial jobless claims in the US rose by 5,000 to 215,000, exceeding expectations, reflecting weakness in the labor market, which may heighten investor concerns about the economic outlook.
- Earnings Season Insights: As of Thursday, 83% of the 482 S&P 500 companies reported earnings above estimates, with Q1 earnings projected to grow by 12% year-on-year, demonstrating corporate resilience despite a slowdown in the tech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy A?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on A
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 135.380
Low
160.00
Averages
171.67
High
180.00
Current: 135.380
Low
160.00
Averages
171.67
High
180.00
About A
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Performance Exceeds Expectations: Agilent Technologies reported Q1 revenues and earnings that surpassed market expectations, indicating strong demand in the biotechnology and pharmaceutical sectors, which is likely to drive stock price increases.
- Revenue Growth: The company's revenue growth rate exceeded analyst forecasts, reflecting its competitiveness in high-growth markets and potentially attracting more investor interest.
- Improved Profitability: Agilent's earnings per share outperformed expectations, demonstrating improvements in cost control and operational efficiency, which enhances market confidence in its future profitability.
- Positive Market Reaction: Following the strong performance, Agilent Technologies' stock rallied in the market, significantly boosting investor optimism regarding its future growth potential.
See More
- Strong Earnings Report: Agilent Technologies reported $1.83 billion in revenue for Q2 2026, a 10% year-over-year increase, with net income rising 14% to $423 million or $1.49 per share, exceeding analyst expectations and demonstrating robust market performance.
- Growth Across Segments: All three reporting units experienced revenue growth, led by the Applied Markets Group with a 14% increase to $344 million, followed by the life sciences and diagnostics segment with a 12% boost to $732 million, and Agilent CrossLab's revenue rising 6% to $759 million, reflecting the overall health of the company's operations.
- Upgraded Full-Year Guidance: Supported by strong performance, Agilent's management raised its full-year 2026 revenue guidance to $7.39 billion to $7.49 billion, while also increasing its adjusted net income projection to $6 to $6.10 per share, indicating confidence in future earnings.
- Positive Market Reaction: Investors reacted positively to the earnings report, driving Agilent's stock price up by 17.25% during the trading session, thereby enhancing the company's market capitalization and solidifying its position in the medical device and healthcare technology sectors.
See More
- Significant Performance Growth: Agilent Technologies reported $1.83 billion in revenue for Q2 2026, marking a 10% year-over-year increase and surpassing analyst expectations of $1.8 billion, demonstrating the company's robust performance in the medical device and healthcare tech sectors.
- Net Income Increase: The company's non-GAAP net income reached $423 million, a 14% increase from the previous year, with earnings per share at $1.49, reflecting a sustained enhancement in profitability.
- Growth Across Business Units: All three of Agilent's reporting units saw revenue growth, with the Applied Markets Group rising 14% to $344 million and the Life Sciences and Diagnostics segment increasing 12% to $732 million, showcasing the resilience of the company's diversified business.
- Upward Revision of Annual Guidance: Management raised the lower end of its 2026 revenue guidance to $7.39 billion to $7.49 billion, while also adjusting the non-GAAP net income projection to $6 to $6.10 per share, indicating strong confidence in future performance.
See More
- Market Recovery: The S&P 500 rose by 0.58% and the Nasdaq 100 climbed 0.84%, reaching all-time highs, reflecting market optimism following the US-Iran ceasefire agreement, which may promote economic stability.
- Economic Data Impact: The US April core PCE price index increased by 3.3% year-on-year, meeting expectations, but the unexpected 1.1% decline in April capital goods orders indicates economic recovery fragility, potentially influencing the Fed's monetary policy decisions.
- Rising Unemployment Claims: Initial jobless claims in the US rose by 5,000 to 215,000, exceeding expectations, reflecting weakness in the labor market, which may heighten investor concerns about the economic outlook.
- Earnings Season Insights: As of Thursday, 83% of the 482 S&P 500 companies reported earnings above estimates, with Q1 earnings projected to grow by 12% year-on-year, demonstrating corporate resilience despite a slowdown in the tech sector.
See More
- Market Recovery: The S&P 500 index rose by 0.44% and the Nasdaq 100 climbed by 0.62%, indicating a recovery after early losses, reflecting cautious optimism among investors regarding the economic outlook.
- Economic Data Impact: The April core PCE price index increased by 3.3% year-on-year, meeting expectations and indicating persistent inflationary pressures, while April new home sales fell by 6.2% to 622,000, highlighting weakness in the housing market.
- Fed Policy Expectations: Concerns from Fed officials about inflation are intensifying, potentially leading to future rate hikes, with the market pricing in only a 3% chance of a rate cut at the June FOMC meeting, reflecting investor caution regarding monetary policy.
- Corporate Earnings Performance: So far, 83% of the 479 S&P 500 companies have exceeded earnings expectations, with Q1 earnings projected to rise by 12% year-on-year, demonstrating resilience in corporate profitability despite a slowdown in the tech sector.
See More
- Quantum Computing Investment: IBM disclosed in a regulatory filing that it will invest over $10 billion in quantum computing over the next five years, a move expected to enhance the company's competitiveness in cutting-edge technology and solidify its market leadership.
- Chipmaker Stock Surge: Arm Holdings' shares jumped over 15% after Mizuho raised its price target from $290 to $360, anticipating strong growth from internal CPU demand in 2027, which boosts market confidence in its future performance.
- Rail Merger Halted: Shares of Norfolk Southern and Union Pacific fell about 4% after the Surface Transportation Board halted its review of the proposed $71.5 billion merger, indicating regulatory concerns that could impact future market consolidation.
- Cloud Platform Performance: Snowflake's stock soared 37%, with expectations for a second-quarter adjusted operating margin of 12.5%, exceeding analysts' forecast of 11.9%, demonstrating its strong growth potential in the cloud computing market.
See More











